
Conference Menu
Current Event
Overview PDF Download Press Pass Request Brochure
Join our LinkedIn Group

Corporate Sponsors



Media Partners

.jpg?n=2611)







.jpg?n=2155)






|
|
|
|
|
- Speaker Presentations
- Poster Abstracts
- and More!
|


.jpg)
CONFERENCE HIGHLIGHTS
New Tools and Techniques to Improve the Productivity and ROI
Accelerate Development While Reducing Risk and Attrition
Focus Resources on the Most Promising Candidates
Maximize the Total Value of Your Drug Development Pipeline
Featuring a Pre-Conference Short Course:
Tuesday, October 13 (9:00 am - 12:00 pm)
Predicting Outcomes in Pre-Clinical Development John Arrowsmith, Ph.D., Executive Director and Head, Competitive Intelligence, Pfizer Global Research and Development
The course will explore some of the fundamental factors that go into a POC decision. It will analyze the underlying science that drives those decisions and how to influence investments and behaviors to make more of the right choices and fewer wrong choices.
This interactive short course will cover: • Introduction to the general idea of attrition, pointing out obvious productivity and economic impacts. • Investigate causes of attrition. • Focus on Phase II attrition specifically and the importance of POC. • Group discussion on defining a POC and how far in advance of a POC the decision criteria need to be agreed. • Discuss how and why things go wrong when a POC fails. • Novel and non-novel POC's, the Proof of Mechanism and translation from pre-clinical to clinical for safety and efficacy measures. • Types of risk being taken on at POC, since all are not are born equal. • Group discussion around planning and executing POC's. • Leveraging benchmark data and use after action reviews. • Final wrap up discussion and Q&A.
*Separate Registration Required
|
WHITE PAPER
Click here to download the "Understanding The 505(b)(2) Approval Pathway" white paper
|
|
|